184 related articles for article (PubMed ID: 17374436)
1. Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop.
Sylvester R
Eur Urol; 2007 Jun; 51(6):1748-50. PubMed ID: 17374436
[No Abstract] [Full Text] [Related]
2. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
3. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
4. Intravesical chemotherapy.
Prout GR
Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
[No Abstract] [Full Text] [Related]
5. Risk-adapted use of intravesical chemotherapy.
Lerner SP; Au JL
BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
[No Abstract] [Full Text] [Related]
6. Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given?
Bouffioux C
Prog Clin Biol Res; 1985; 185B():47-55. PubMed ID: 4034591
[No Abstract] [Full Text] [Related]
7. Bladder cancer--resection/ablation.
Corica FA; Keane TE
Surg Oncol Clin N Am; 2005 Apr; 14(2):321-52. PubMed ID: 15817242
[No Abstract] [Full Text] [Related]
8. Re: Agrawal et al.: The safety and efficacy of different doses of bacillus Calmette-Guérin in superficial bladder transitional cell carcinoma. (Urology 2007;70:1075-1078).
Simone G; Leonardo C; Gallucci M
Urology; 2008 Nov; 72(5):1187-8. PubMed ID: 18774592
[No Abstract] [Full Text] [Related]
9. [International Consensus Panel--treatment strategies for superficial bladder cancer].
Adler S; St Niclas M
Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
[No Abstract] [Full Text] [Related]
10. The optimal management of T1G3 bladder cancer.
Emiliozzi P; Pansadoro A; Pansadoro V
BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
[No Abstract] [Full Text] [Related]
11. Treatment of superficial carcinoma of the bladder.
Paulson DF
Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
[No Abstract] [Full Text] [Related]
12. Intravesical and systemic chemotherapy of murine bladder cancer.
Soloway MS
Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
[No Abstract] [Full Text] [Related]
13. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
[No Abstract] [Full Text] [Related]
14. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
15. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
McHugh LA; Griffiths TR
BJU Int; 2004 Jul; 94(1):193. PubMed ID: 15217467
[No Abstract] [Full Text] [Related]
16. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
de Reijke TM
Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
[No Abstract] [Full Text] [Related]
17. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Bochner BH
Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
[No Abstract] [Full Text] [Related]
19. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
[TBL] [Abstract][Full Text] [Related]
20. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
